|1.||Yusuf, Salim: 50 articles (03/2015 - 09/2003)|
|2.||McMurray, John J V: 48 articles (09/2015 - 09/2003)|
|3.||Swedberg, Karl: 48 articles (03/2015 - 09/2003)|
|4.||Pfeffer, Marc A: 47 articles (03/2015 - 09/2003)|
|5.||Granger, Christopher B: 44 articles (03/2015 - 09/2003)|
|6.||Michelson, Eric L: 40 articles (01/2014 - 09/2003)|
|7.||Olofsson, Bertil: 25 articles (07/2010 - 05/2003)|
|8.||Solomon, Scott D: 24 articles (03/2015 - 10/2004)|
|9.||Ostergren, Jan: 21 articles (11/2011 - 09/2003)|
|10.||Fagan, Susan C: 16 articles (08/2015 - 03/2006)|
|1.||Hypertension (High Blood Pressure)
01/01/2014 - "In conclusion, the switching therapy to increased dose of candesartan caused significant reductions in office and ambulatory BP levels, and improved the attainment of target BP levels in patients with uncontrolled hypertension treated with a medium dose of ARBs. "
06/01/2014 - "Once-daily azilsartan improved sleep trough surge and prewaking surge to a greater extent than candesartan in Japanese patients with grade I-II essential hypertension. "
09/01/2013 - "Once-daily azilsartan improved non-dipping night-time SBP to a greater extent than candesartan in Japanese patients with grade I-II essential hypertension."
11/08/2005 - "The known renal protective effects of candesartan in hypertension may be related to the improvement of mitochondrial function. "
11/01/2004 - "In patients with hypertension, candesartan monotherapy has been shown to be safe and effective. "
01/01/2009 - "Recent studies have shown candesartan to be an effective therapy for heart failure (HF) patients, producing a significant reduction in cardiovascular mortality and morbidity. "
10/01/2006 - "Recent studies have shown candesartan to be an effective therapy for heart failure patients, producing a significant reduction in mortality and morbidity. "
05/01/2005 - "Moreover, the CHARM-preserved study suggested that candesartan is beneficial in patients with heart failure and preserved left-ventricular systolic function. "
07/01/2006 - "More recently, candesartan was shown to be an effective therapy for heart failure patients, producing a significant reduction in mortality and morbidity. "
08/01/2004 - "Candesartan was beneficial in heart failure patients with or without left ventricular systolic dysfunction."
05/01/2003 - "In elderly hypertensive patients, a slightly more effective blood pressure reduction during candesartan-based therapy, compared with control therapy, was associated with a modest, statistically non-significant, reduction in major cardiovascular events and with a marked reduction in non-fatal stroke. "
10/01/2002 - "This trial is expected to clarify whether early treatment with candesartan during the acute stage of stroke is beneficial for the neurological outcome or prognosis."
07/01/2005 - "The results indicate that candesartan-based antihypertensive treatment is cost-effective for the prevention of nonfatal stroke."
05/01/2015 - "These results show that candesartan directly improves cell function and viability of brain capillary endothelial cells under OGD/reoxygenation, suggesting that the protective effects of candesartan on ischemic stroke are related to protection of the BBB."
09/01/2011 - "Candesartan was safe and effective for BP control in acute stroke patients. "
01/01/2015 - "CXCR4 antagonism markedly reduced cardiac fibrosis in both models of diabetes, similar in magnitude to that seen with candesartan. "
01/01/2015 - "These data show that candesartan, at a dose sufficient to reduce blood pressure and LVH, did not cause regression of LA fibrosis in hypertensive rats. "
07/01/2012 - "In addition, the fibrosis score was significantly reduced from 3.4 ± 1.4 to 3.1 ± 1.5 (P = 0.005) in the candesartan group. "
07/01/2012 - "According to the Laennec fibrosis system, candesartan showed significantly higher rates of histological improvements (ITT, 33.3% vs. 11.6%, P = 0.020). "
09/01/2011 - "Candesartan reduced CTGF expression and attenuated the fibrosis in diabetic rat atria. "
01/01/1999 - "In Langendorff-perfused rat hearts, candesartan, in a dose-related manner, improved left ventricular functional recovery and reduced the no-reflow area following global ischemia and reperfusion. "
07/01/1999 - "Starting 60 min before ischemia, two groups of pigs (n = 6 in each) received either candesartan (25 micrograms/kg bolus followed by a continuous infusion at a rate of 14 micrograms/kg/h) or the corresponding volume of vehicle throughout the study period. "
05/01/2015 - "Candesartan improves ischemia-induced impairment of the blood-brain barrier in vitro."
11/01/2014 - "In addition, pretreatment with candesartan significantly reduced ischemia induced tissue swelling. "
01/01/2014 - "Vehicle and non-hypotensive doses of candesartan (0.1 mg/kg) were administered one hour before ischemia. "
|1.||Angiotensin Receptors (Angiotensin II Receptor)
|3.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|1.||Transplantation (Transplant Recipients)
|3.||Homologous Transplantation (Allograft)
|4.||Electric Countershock (Cardioversion)